Favorable clinical outcomes and anti-mycobacterial efficacy of pretomanid in patients with highly resistant tuberculosis: A review
- 26 October 2023
- journal article
- review article
- Published by Elsevier in Indian Journal of Tuberculosis
- Vol. 71, S130-S135
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of managementLung India, 2018
- Extensively drug resistant tuberculosis in Mali: a case reportBMC Research Notes, 2017
- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible TuberculosisClinical Infectious Diseases, 2016
- Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant TuberculosisCold Spring Harbor Perspectives in Medicine, 2015
- Risk Factors for TuberculosisPulmonary Medicine, 2013
- Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824Antimicrobial Agents and Chemotherapy, 2012
- QT Prolongation and Torsade de Pointes Induced by Fluoroquinolones: Infrequent Side Effects from Commonly Used MedicationsCardiology, 2011
- Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2009
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO ReleaseScience, 2008
- A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisNature, 2000